CRA CRA Adverse Event Reporting & Safety Monitoring 1 — Questions and Answers
Question 1: According to ICH E6(R2), what is the definition of a Serious Adverse Event (SAE)?
- Any untoward medical occurrence that requires a dose reduction
- Any untoward medical occurrence that results in death, hospitalization, disability, or is life-threatening (Correct answer)
- Any adverse event that causes the subject to withdraw from the study
- Any adverse event classified as Grade 3 or higher by CTCAE
Correct answer: Any untoward medical occurrence that results in death, hospitalization, disability, or is life-threatening
ICH E6(R2) defines an SAE as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, results in persistent disability, or is a congenital anomaly.
Question 2: Under FDA regulations (21 CFR 312.32), within what timeframe must a sponsor report a fatal or life-threatening unexpected serious adverse drug reaction (SUSAR) to the FDA?
- Within 7 calendar days (Correct answer)
- Within 15 calendar days
- Within 30 calendar days
- Within 24 hours
Correct answer: Within 7 calendar days
Fatal or life-threatening unexpected serious adverse drug reactions must be reported to the FDA within 7 calendar days of the sponsor first receiving notice.
Question 3: What distinguishes an 'unexpected' adverse drug reaction from an 'expected' one in a clinical trial?
- An unexpected ADR is more severe than expected based on CTCAE
- An unexpected ADR is not consistent in nature or severity with the investigator's brochure (Correct answer)
- An unexpected ADR occurs in more than 5% of study participants
- An unexpected ADR requires hospitalization while an expected one does not
Correct answer: An unexpected ADR is not consistent in nature or severity with the investigator's brochure
An adverse drug reaction is 'unexpected' when its nature, severity, or frequency is not consistent with the information in the Investigator's Brochure (IB) or current product labeling.
Question 4: Which regulatory document is the investigator's primary reference for assessing whether an SAE is expected or unexpected?
- The clinical study protocol
- The informed consent form
- The Investigator's Brochure (IB) (Correct answer)
- The site monitoring report
Correct answer: The Investigator's Brochure (IB)
The Investigator's Brochure contains all known safety and efficacy information about the investigational product and serves as the reference for expectedness assessment.
Question 5: In a clinical trial, what is the primary responsibility of a Data Safety Monitoring Board (DSMB)?
- To approve protocol amendments before submission to the IRB
- To independently review accumulating safety and efficacy data and recommend stopping or continuing the trial (Correct answer)
- To audit site compliance with GCP regulations
- To adjudicate all adverse event reports from investigators
Correct answer: To independently review accumulating safety and efficacy data and recommend stopping or continuing the trial
A DSMB independently reviews unblinded accumulating data to safeguard participant safety and ensure trial integrity, with authority to recommend stopping the trial.
Question 6: The Common Terminology Criteria for Adverse Events (CTCAE) grading scale is used to standardize the severity of adverse events. What does a Grade 5 event indicate?
- A severe adverse event requiring hospitalization
- A life-threatening event requiring urgent intervention
- Death related to the adverse event (Correct answer)
- A disabling adverse event affecting daily activities
Correct answer: Death related to the adverse event
CTCAE Grade 5 is defined as death related to the adverse event, making it the most severe category in the grading system.
CRA CRA Adverse Event Reporting & Safety Monitoring 1
According to ICH E6(R2), what is the definition of a Serious Adverse Event (SAE)?